Comparative Clinical and Therapeutic Landscape of Aflibercept Biosimilars (YESAFILI), High-Dose Aflibercept 8 mg (EYLEA HD), and Faricimab (VABYSMO): A Structured Narrative Review

Authors
Category Systematic review
JournalClin. Ophthalmol.
Year 2026
This article has no abstract
Epistemonikos ID: 6869fbe49cee35b3b2333766423c7da23b3e76b1
First added on: Oct 24, 2026